Back to News
Market Impact: 0.2
Celularity Inc. Announces Exclusive Peptide API Manufacturing Collaboration with Vesalius Longevity Labs on October 29, 2026
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Celularity announced an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs on October 29, 2026. Celularity will be the exclusive partner for finish manufacturing Vesalius’s Peptual peptide APIs; the provided article text includes no financial terms or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CELU0.55
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- PC chip plunge wipes out a quarter of Intel’s value
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up